((自动化翻译由路透提供，请见免责声明 ))
9月12日 - ** 药物开发商Fulcrum Therapeutics 股价盘前暴跌70.62%，至2.60美元
** 该公司称， (link)，其治疗遗传性肌肉疾病的实验药物在一项后期研究中未能达到主要目标
** 该公司正在对其口服药物losmapimod进行测试，测试对象是260名面岬肱肌营养不良症患者(FSHD)，这些患者在48周的时间里要么接受该疗法，要么接受安慰剂治疗。
** Adds 将暂停未来 losmapimod 的开发
** FSHD是一种罕见的遗传性肌肉疾病，脸部、肩胛骨和上臂肌肉受影响最大
** 截至上一交易日收盘，股价年累计上涨约 31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.